cobas EGFR Mutation Test, v2.0
Roche · Decision date Oct 27, 2026
What did the FDA decide?
The FDA record shows a 30-day notice for the cobas® EGFR Mutation Test, v2.0, submitted under P120019/S044 and marked OK30 on 2026-10-27. The stated purpose is to change the manufacturing process for oligonucleotides, classified under the supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The device category is Somatic gene mutation detection system, product code OWD, in Pathology, with Roche as applicant.
P120019 ties this filing to an existing PMA, but a supplement is not a new approval of the whole test system, and a manufacturing notice is not an original PMA. The notice gives no details on which oligonucleotides, what process step changed, or what validation supported the change, and it does not report data on analytical performance, safety, or clinical effectiveness. Those specifics are absent from the supplied fields and remain unknown; the OK30 decision is a regulatory record, not independent proof of any such outcome.
FDA approval order statement
to change the manufacturing process for oligonucleotides
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Oct 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P120019/S044
- Regulatory pathway
- PMA supplement
- Applicant
- Roche
- Product code
- OWD
- Decision code
- OK30
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
For the original device and its historical approval scope, see PMA P120019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P120019 · Original PMA
COBAS EGFR MUTATION TEST
P120019/S044 received
Application receipt date recorded by FDA.
P120019/S044 · FDA decision
30-Day Notice
P120019/S045 · Related supplement
Roche cobas EGFR Mutation Test, v2.0
Timeline entries are records held by MedtechLedger for P120019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COBAS EGFR MUTATION TESTP120019 | Roche | PMA approval | May 14, 2013 | FDA |
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas KRAS Mutation TestP140023/S033 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4300 Hacienda Dr., P.O. Box 9002, Peasanton, CA, 94588
Sources and methodology
- Original FDA record: P120019/S044
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


